Key statistics dashboard for Cyclerion Therapeutics, Inc. (CYCN). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Cyclerion Therapeutics, Inc. operates as a biopharmaceutical company in the clinical development phase, concentrating on the discovery, advancement, and commercialization of therapeutic agents for debilitating central nervous system (CNS) disorders. Their leading experimental compound, CY6463, is a soluble guanylate cyclase (sGC) stimulator designed to cross the blood-brain barrier.
Stock Data
| Price | $23.52 |
| Market Cap | $16M |
| Beta | 0.89 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -1.95 |
| Price / Book | 2.81 |
| P/S | 8.28 |
| P/FCF | -3.53 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 61.58% |
| EBIT Margin | -353.00% |
| EBITDA Margin | -353.00% |
| Operating Margin | -359.16% |
| Net Margin | -353.00% |
Financial Health
| Current Ratio | 0.82 |
| Quick Ratio | 0.82 |
| Cash Ratio | 0.75 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 3.13 |
| Book Value per share | 8.38 |
| Cash per share | 2.29 |
| FCF per share | -7.33 |
| Tangible Book Value per share | 8.38 |
| Dividend per share | 0.00 |
Related companies: ADXN · AIM · KTTA · NBY · PLRZ · QNRX · RADX
Explore sector: Healthcare · Biotechnology
More sections of CYCN: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks